Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial
Conclusions Final long-term safety ALSYMPCA analysis shows that radium-223 remained well tolerated, with low myelosuppression incidence and no new safety concerns. Patient summary Updated Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial findings show that radium-223 remained well tolerated during treatment and up to 3 yr after each patient's first injection. Three-year safety follow-up of Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial patients with castration-resistant prostate cancer and symptomatic bone metastases revealed a continued low incidence of myelosuppression, minimal nonhematologic adverse events, and secondary malignancies (none related to treatment) in four radium-223 patients and three placebo patients.
Publication date: Available online 8 July 2020Source: Comparative Immunology, Microbiology and Infectious DiseasesAuthor(s): Abdelfattah Selim, Ameer A. Megahed, Sahar Kandeel, Abdelhamed Abdelhady
Publication date: Available online 9 July 2020Source: Saudi Pharmaceutical JournalAuthor(s): Saranya Rameshbabu, Safia A. Messaoudi, Zeyad Ibrahim Alehaideb, Mohammed Syed Ali, Anuradha Venktraman, Hala Alajmi, Hamad Al-Eidi, Sabine Matou-Nasri
Publication date: Available online 8 July 2020Source: PhytomedicineAuthor(s): Safaa Yehia Eid, Mohammad Ahmad Althubiti, Michael Wink, Mahmoud Zaki El-Readi
PANCREATIC cancer is harder to treat in the later stages so it is important to act on the warning signs as soon as they appear. One warning can be seen in the colour of your urine.
Conclusion: Lower cutoff screening values can be used to exclude α0-thalassemia in the Hb E trait yielding a higher specificity in a normal RDW condition. This can save the cost and labor of DNA testing. PMID: 32633642 [PubMed - in process]
Publication date: August 2020Source: Cancer Epidemiology, Volume 67Author(s): Sophie D. Fosså, Alv A. Dahl, Tor Å. Myklebust, Cecile E. Kiserud, Ragnhild Nome, Olbjørn H. Klepp, Marianne Brydøy, Hege S. Haugnes